Linezolid Injection |
Zyvox Injection |
Clinical Trial: Linezolid in the Treatment of Complicated Skin and Soft Tissue due to Methicillin-Resistant Staphylococcus Aureus
This study is currently recruiting patients.
|
Purpose
This is a Phase IV randomized, multi-center, open label trial to compare the clinical safety and efficacy of linezolid to vancomycin in the treatment of complicated skin and soft tissue infections due to methicillin-resistant staphylococcus aureus in adult subjects hospitalized for at least one day.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Staphylococcal Skin Infections Soft Tissue Infections | Drug: Linezolid Drug: Vancomycin | Phase IV |
MedlinePlus related topics: Bacterial Infections; Skin Diseases; Staphylococcal Infections
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment
Official Title: Linezolid in the Treatment of Subjects with Complicated Skin and Soft Tissue Proven to be due to Methicillin-Resistant Staphylococcus Aureus
Expected Total Enrollment: 1200
Study start: August 2004
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
- Hospitalized male/female subjects at least 18 years of age
- Signs and symptoms consistent with infection
- Infection suspected to be due to Methicillin Resistant Staphylococcus Aureus
- Subjects excluded with necrotizing fasciitis, gas gangrene, osteomyelitis
- Subjects excluded if treated with a previous antibiotic with known activity against Methicillin Resistant Staphylococcus Aureus for more than 24 hours
Location and Contact Information
Alabama
Pfizer Investigational Site, Montgomery, Alabama, 36106, United States; Recruiting
California
Pfizer Investigational Site, Palm Springs, California, 92262, United States; Recruiting
Pfizer Investigational Site, Rancho Mirage, California, 92270, United States; Recruiting
Colorado
Pfizer Investigational Site, Denver, Colorado, 80205, United States; Recruiting
Pfizer Investigational Site, Denver, Colorado, 80218, United States; Recruiting
Connecticut
Pfizer Investigational Site, New Haven, Connecticut, 06520, United States; Recruiting
Pfizer Investigational Site, New Haven, Connecticut, 06515, United States; Recruiting
Florida
Pfizer Investigational Site, Atlantis, Florida, 33462, United States; Recruiting
Pfizer Investigational Site, Pensacola, Florida, 32501, United States; Recruiting
Georgia
Pfizer Investigational Site, Blue Ridge, Georgia, 30513, United States; Recruiting
Illinois
Pfizer Investigational Site, Springfield, Illinois, 62701, United States; Recruiting
Pfizer Investigational Site, Springfield, Illinois, 62702, United States; Recruiting
Pfizer Investigational Site, North Chicago, Illinois, 60064, United States; Recruiting
Pfizer Investigational Site, Decatur, Illinois, 62526, United States; Recruiting
Maryland
Pfizer Investigational Site, Baltimore, Maryland, 21201, United States; Recruiting
Michigan
Pfizer Investigational Site, St. Joseph, Michigan, 49103, United States; Recruiting
Minnesota
Pfizer Investigational Site, Minneapolis, Minnesota, 55422, United States; Recruiting
Montana
Pfizer Investigational Site, Butte, Montana, 59701, United States; Recruiting
New York
Pfizer Investigational Site, Poughkeepsie, New York, 12601, United States; Recruiting
North Carolina
Pfizer Investigational Site, Winston Salem, North Carolina, 27103, United States; Recruiting
Ohio
Pfizer Investigational Site, Akron, Ohio, 44304, United States; Recruiting
Pfizer Investigational Site, Columbus, Ohio, 43215, United States; Recruiting
Pennsylvania
Pfizer Investigational Site, Philadelphia, Pennsylvania, 19140, United States; Recruiting
Tennessee
Pfizer Investigational Site, Ducktown, Tennessee, 37326, United States; Recruiting
Utah
Pfizer Investigational Site, St. George, Utah, 84770, United States; Recruiting
Argentina
Pfizer Investigational Site, Buenos Aires, C1425DQK, Argentina; Recruiting
Pfizer Investigational Site, Buenos Aires, Argentina; Recruiting
Pfizer Investigational Site, Cordoba, 5000, Argentina; Recruiting
Argentina, Buenos Aires
Pfizer Investigational Site, Loma Hermosa, Buenos Aires, 1653, Argentina; Recruiting
More Information
Record last reviewed: March 2005
Last Updated: March 15, 2005
Record first received: July 9, 2004
ClinicalTrials.gov Identifier: NCT00087490
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Linezolid Injection (Drug Digest)
- Zyvox Injection (Drug Digest)

Not Signed In -


